Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis

OBJECTIVE: RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet medical need. We evaluated the effects of baseline characteristics, including prior bDMARD exposure, on baricitinib efficacy and safety. METHODS: RA-BEACON patients (previously reported) had moderate to severe RA wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C, Kremer, Joel M, Kartman, Cynthia E, Schlichting, Douglas E, Xie, Li, Carmack, Tara, Pantojas, Carlos, Sanchez Burson, Juan, Tony, Hans-Peter, Macias, William L, Rooney, Terence P, Smolen, Josef S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Basic and Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913638/
https://www.ncbi.nlm.nih.gov/pubmed/29415145
http://dx.doi.org/10.1093/rheumatology/kex489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913638/
https://www.ncbi.nlm.nih.gov/pubmed/29415145
http://dx.doi.org/10.1093/rheumatology/kex489

Ejemplares similares